

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.


Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
SHANGHAI–Zoetis Inc. (NYSE: ZTS) today celebrated the start of construction on a combined global manufacturing and supply and research and development center in Suzhou, China, with a traditional groundbreaking ceremony. The new facility will focus […]
CytoDyn, Inc. (OTC: CYDY) Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before […]
FORT LAUDERDALE, Fla.—-MEDNAX, Inc. (NYSE:MD), today announced the acquisition of Women’s Radiology Associates, LLP, a private radiology physician group based in Houston. The practice will integrate with Synergy Radiology Associates, a MEDNAX-affiliated physician practice, also […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
